Moloney Securities Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $302K | Buy |
2,725
+358
| +15% | +$40.7K | 0.04% | 361 |
|
|
2025
Q2 | $262K | Sell |
2,367
-164
| -6% | -$17.5K | 0.03% | 391 |
|
|
2025
Q1 | $284K | Sell |
2,531
-22,629
| -90% | -$2.33M | 0.04% | 360 |
|
|
2024
Q4 | $2.32M | Sell |
25,160
-815
| -3% | -$73.4K | 0.31% | 80 |
|
|
2024
Q3 | $2.18M | Buy |
25,975
+1,326
| +5% | +$101K | 0.29% | 84 |
|
|
2024
Q2 | $1.69M | Buy |
24,649
+5,960
| +32% | +$398K | 0.24% | 97 |
|
|
2024
Q1 | $1.37M | Sell |
18,689
-537
| -3% | -$41.3K | 0.21% | 124 |
|
|
2023
Q4 | $1.56M | Sell |
19,226
-344
| -2% | -$26.8K | 0.25% | 98 |
|
|
2023
Q3 | $1.47M | Sell |
19,570
-298
| -1% | -$22.9K | 0.26% | 91 |
|
|
2023
Q2 | $1.53M | Buy |
19,868
+1,378
| +7% | +$110K | 0.27% | 91 |
|
|
2023
Q1 | $1.53M | Sell |
18,490
-2,788
| -13% | -$231K | 0.29% | 94 |
|
|
2022
Q4 | $1.83M | Sell |
21,278
-552
| -3% | -$43.7K | 0.4% | 66 |
|
|
2022
Q3 | $1.35M | Sell |
21,830
-345
| -2% | -$21.8K | 0.33% | 80 |
|
|
2022
Q2 | $1.37M | Sell |
22,175
-99
| -0.4% | -$6.13K | 0.32% | 85 |
|
|
2022
Q1 | $1.32M | Buy |
22,274
+1,449
| +7% | +$92.6K | 0.26% | 115 |
|
|
2021
Q4 | $1.51M | Buy |
20,825
+1,018
| +5% | +$70.1K | 0.26% | 96 |
|
|
2021
Q3 | $1.38M | Buy |
19,807
+781
| +4% | +$54.9K | 0.25% | 106 |
|
|
2021
Q2 | $1.31M | Buy |
19,026
+202
| +1% | +$13.5K | 0.24% | 111 |
|
|
2021
Q1 | $1.22M | Sell |
18,824
-1,406
| -7% | -$90.7K | 0.24% | 114 |
|
|
2020
Q4 | $1.18M | Sell |
20,230
-1,249
| -6% | -$75.4K | 0.26% | 103 |
|
|
2020
Q3 | $1.36M | Buy |
21,479
+263
| +1% | +$18.2K | 0.36% | 82 |
|
|
2020
Q2 | $1.63M | Sell |
21,216
-1,311
| -6% | -$100K | 0.47% | 74 |
|
|
2020
Q1 | $1.68M | Buy |
22,527
+622
| +3% | +$43K | 0.6% | 55 |
|
|
2019
Q4 | $1.42M | Buy |
21,905
+17,633
| +413% | +$1.15M | 0.44% | 63 |
|
|
2019
Q3 | $271K | Sell |
4,272
-280
| -6% | -$18.3K | 0.09% | 249 |
|
|
2019
Q2 | $308K | Sell |
4,552
-611
| -12% | -$40.2K | 0.1% | 218 |
|
|
2019
Q1 | $336K | Buy |
5,163
+470
| +10% | +$31.2K | 0.12% | 203 |
|
|
2018
Q4 | $294K | Buy |
4,693
+285
| +6% | +$19.9K | 0.12% | 197 |
|
|
2018
Q3 | $340K | Buy |
4,408
+1
| +0% | +$76 | 0.12% | 194 |
|
|
2018
Q2 | $312K | Sell |
4,407
-52
| -1% | -$3.67K | 0.12% | 202 |
|
|
2018
Q1 | $336K | Buy |
4,459
+232
| +5% | +$18.4K | 0.14% | 189 |
|
|
2017
Q4 | $303K | Hold |
4,227
| – | – | 0.13% | 192 |
|
|
2017
Q3 | $342K | Hold |
4,227
| – | – | 0.15% | 173 |
|
|
2017
Q2 | $299K | Sell |
4,227
-728
| -15% | -$48.4K | 0.15% | 179 |
|
|
2017
Q1 | $337K | Sell |
4,955
-1,428
| -22% | -$100K | 0.17% | 161 |
|
|
2016
Q4 | $457K | Buy |
+6,383
| New | +$474K | 0.28% | 116 |
|
Other funds holding GILD
Moloney Securities Asset Management's GILD Position: Q3 2025 in Review
Moloney Securities Asset Management increased its Gilead Sciences (GILD) stake by 15% in Q3 2025, buying an estimated $40.7K and bringing the position to 2,725 shares worth $302K. The position accounts for 0.04% of the portfolio, ranked #361.
Moloney Securities Asset Management first reported a position in GILD in Q4 2016 and has held it in 36 quarters since. The position peaked at $2.32M in Q4 2024. 2,027 funds tracked by Wall St. Rank hold GILD as of Q3 2025.
- Moloney Securities Asset Management held 2,725 shares of Gilead Sciences worth $302K as of Q3 2025.
- Moloney Securities Asset Management bought 358 Gilead Sciences shares in Q3 2025, an estimated $40.7K.
- Gilead Sciences made up 0.04% of Moloney Securities Asset Management's portfolio in Q3 2025, its #361 holding.
- Moloney Securities Asset Management first reported a position in Gilead Sciences in Q4 2016 and has held it in 36 quarters since.
- Moloney Securities Asset Management's Gilead Sciences position peaked at $2.32M in Q4 2024.
- 2,027 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.
Based on Moloney Securities Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.